
TSE:WELL
This summary was created by AI, based on 13 opinions in the last 12 months.
WELL Health Technologies is perceived as a company with potential, particularly given its focus on electronic medical records and clinic operations. Reviews highlight a recent struggle with execution, particularly post-pandemic, and frustrations related to acquisitions that haven't significantly moved the stock price. Analysts note a divergent sentiment towards the stock, with many awaiting catalysts for a price rebound, especially as they divest from less favorable US operations. Despite impressive revenue growth signals and an attractive valuation at around 9-10x PE, concerns over competition and regulatory scrutiny remain prevalent, leaving experts in a cautious wait-and-see mode about the company's longer-term prospects.
Great company. Management's done well on M&A front. Delayed financials, not a good sign; a US company they own is being investigated. Red flag. He still has faith in management. Watch the next month very carefully; further delay is a double-red flag, resolution would represent a very strong buying opportunity.
He is looking at it. It is very cheap and starting to move, with metrics looking pretty attractive now. It looks like we'll see a more focused company in the future. There was a bubble in the health tech sector but things are sorting themselves out and it looks good for investment. You could probably start buying.
Has a lid on it going back 3 years. There is no right or wrong answer, but when you're coming into an old resistance point, you have to have a catalyst to get through. Remember, people sold (didn't like) this stock at that peak level (around $5.50). And now it's approaching that level.
If there's a catalyst to break through, it will, but keep in mind that it has to be a pretty big catalyst. If there's not a huge change to the company, he'd probably look to sell really soon.
It is a really interesting mid cap of about $1 billion. It is very well managed and has made a couple of really strong acquisitions. It has increased its margins and revenue and upped its guidance last week. It is also profitable and the growth rate looks really good but the stock has lagged. Management has never strayed from their strategy and is going to grow this business and shift the Canadian market into the digitalized type of world.
Too small for his portfolios. In Canada, rolling up medical practices with a strategy of using technology to reduce administrative burden. In US, has a GI line, as well as virtual mental health and women's care; may spin off the latter two. Valuation ~40x forward PE, rich. He can't get behind that valuation, but progress will be interesting to watch.
Expectations have been high since the beginning; founder's previous success was attributed to this name. Business has changed over time. Good job growing business. Revenue growth is there, profitability is not. Good investment banking client, as they raise money quite often, and so the analysts are favourable to it.